April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Arndt Vogel: CHMP recommended a conditional marketing authorisation for zanidatamab for the treatment of HER2-positive biliary tract cancer
Apr 27, 2025, 16:54

Arndt Vogel: CHMP recommended a conditional marketing authorisation for zanidatamab for the treatment of HER2-positive biliary tract cancer

Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology at Hannover Medical School, shared a post on X:

“CHMP recommended a conditional marketing authorisation for zanidatamab for the treatment of HER2-positive biliary tract cancer
  • based on HERIZON-BTC: ORR 41%
  • Phs-III in 1st line ongoingArndt Vogel: CHMP recommended a conditional marketing authorisation for zanidatamab for the treatment of HER2-positive biliary tract cancer

More posts featuring biliary tract cancer.